Purpose: To develop a new oncolytic herpes simplex virus (oHSV) for glioblastoma (GBM) therapy that will be effective in glioblastoma stem cells (GSC), an important and untargeted component of GBM. One approach to enhance oHSV efficacy is by combination with other therapeutic modalities.
Introduction
Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults (1) . Despite advances in drug development, overall survival has not substantially improved. Recently, cancer stem or tumor-initiating cells have been isolated from solid tumors, including GBM, that are tumorigenic with characteristics of adult stem cells including self-renewal and differentiation into multiple lineages (2) . Glioblastoma stem cells (GSC) are thought to be important in GBM progression, heterogeneity, recurrence, and resistance to therapy and provide an important target for the development of new therapies (3) . Detailed molecular analysis of GBMs has shown that genetic alterations in the phosphoinositide-3-kinase (PI3K)/Akt pathway, including in PTEN and PIK3CA, occur in about 80% of tumors (4, 5) . These molecular changes confer GBMs with proliferative and survival advantages and may play a role in regulating GSCs (6) . There has been rapid growth in the development and clinical testing of small molecule inhibitors of the PI3K/Akt pathway including for glioma (7) . It has been reported that GSCs are sensitive to Akt inhibitors (8, 9) . Unfortunately, the combination of genetic alterations and the number of cross-regulatory feedback loops in the PI3K/Akt pathway raise questions about the likely clinical efficacy of inhibitors alone (7, 10) .
Oncolytic viruses are a distinct class of targeted anticancer agents with unique mechanisms of action compared with other cancer therapies; they selectively replicate in and kill cancer cells (oncolysis), amplifying themselves and spreading but sparing normal tissue. The safety of oncolytic herpes simplex virus (oHSV) therapy has been shown in clinical trials for GBM; however, efficacy remains anecdotal and needs improvement (11, 12) . Combining oHSV with chemotherapeutic drugs is an effective strategy to improve overall efficacy and depending on the specific oHSV mutations and drug, synergistic cancer cell killing can be observed (13) . All oHSV vectors developed for clinical use in the brain contain deletions of the g34.5 gene, the major viral neurovirulence factor, which is associated with attenuated replication, even in cancer cells, and an inability to replicate in GSCs (14, 15) . To overcome these obstacles and target different tumorigenic pathways, we have developed a new class of oHSV vectors for the treatment of tumors in the brain that contain a deletion in the HSV-1 U S 3 gene. U S 3 encodes a serine-threonine kinase that among its many activities includes inhibition of virus-induced apoptosis and Akt activation (16) (17) (18) . As apoptotic pathways are frequently dysfunctional in tumor cells, U S 3 mutants should engender tumor selectivity based on enhanced apoptosis in normal cells, preventing further replication, as was found with R7041 (U S 3 À ) infected human umbilical vein endothelial cell (HUVEC; ref. 18 ). We previously reported that R7041 (i) was efficacious in vitro against a number of cancer cell lines, including glioma U87 and T98G, and in vivo against U87 subcutaneous tumors; (ii) synergized with PI3K/Akt inhibitors; and (iii) was safe after systemic delivery in the periphery (18) . To extend these findings to human GSCs and intracerebral GBM tumor models for possible clinical translation, we constructed a new multimutated oHSV, MG18L [U S 3 deleted and U L 39 (ICP6) negative], which is safe after intracerebral inoculation, replicates well in GSCs, and synergizes with PI3K/Akt pathway inhibitors in killing GSCs in vitro and in vivo through enhanced apoptosis.
Materials and Methods
Cell lines and reagents U87 and T98G human glioma and Vero (African green monkey kidney) cells were obtained from the American Type Culture Collection and used at low-passage number. Human astrocytes were obtained from ScienCell. Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (DMEM-FCS) at 37 C and 5% CO 2 . Human GSCs were isolated as previously described (15) and cultured in EF20 medium composed of Neurobasal medium (Invitrogen) supplemented with 3 mmol/L L-Glutamine (Mediatech), 1Â B27 supplement (Invitrogen), 0.5Â N 2 supplement (Invitrogen), 2 mg/mL heparin (Sigma), 20 ng/mL human EGF (epidermal growth factor; R&D systems), 20 ng/mL human FGF-2 (fibroblast growth factor 2; Peprotech) and 0.5Â penicillin G/streptomycin sulfate/amphotericin B complex (Mediatech). The stem cell features of GBM4, GBM8, and BT74 have been previously described (15) . Spheres were dissociated using NeuroCult Chemical Dissociation kit (StemCell Technologies). Passaged cells were confirmed to be mycoplasma free. LY294002 (LC Laboratories), triciribine (Akt inhibitor V; Santa Cruz Biotechnology), GDC-0941 (Chemdea), BEZ235 (Chemdea), and Z-VAD-FMK (Tocris Bioscience) were dissolved in dimethyl sulfoxide (Sigma-Aldrich).
Viruses
All viruses were constructed on a HSV-1 strain F background. G207 (g34.5D, ICP6 À , LacZ), G47D (g34.5D, ICP6 À , ICP47/ U S 11proD, LacZ), and FD6 (ICP6 À , LacZ) have been previously described (14, 15, 19) . R7041 (U S 3 deleted) was provided by Dr. B. Roizman (University of Chicago, Chicago, IL; ref. 20) . Viruses were grown, purified, and titered on Vero cells (19) .
Construction of MG18L
Construction and characterization of MG18L was as described (19) . Briefly, the 5.3-kb fragment of pKX2-bG3 (from S.K. Weller, University of Connecticut Health Center, Farmington, CT), containing the Escherichia coli lacZ sequence inserted in-frame in U L 39, was cotransfected with R7041 viral DNA into Vero cells using Lipofectamine (Invitrogen). Recombinant viruses, isolated by limiting dilution and identified as plaques staining blue after Xgal histochemistry ( Supplementary Fig. S2A ), were plaque purified 3 times in Vero cells. The genomic structure of MG18L was confirmed by restriction endonuclease digestion and Southern blot analysis ( Supplementary Fig. S1 ).
Viral replication assay
Cells were seeded into 24-well plates (2 Â 10 4 cells/well) in 0.5 mL of media and infected at a multiplicity of infection (MOI) of 1.5 in triplicate. LY294002 was added 6 hours postinfection (pi) and titers determined by plaque assay on Vero cells.
Cell susceptibility assays and Chou-Talalay analysis
Cells were seeded into 96-well plates (5,000 cells/well), and 3.5 days after infection or 3 days after drug treatment MTS assays (Promega) were carried out according to manufacturer's instructions. For Chou-Talalay analysis (21),
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experiments were carried out as described (22) . Doseresponse curves and 50% effective dose values (ED 50 ) were obtained, and fixed ratios of drug and virus and mutually exclusive equations used to determine combination indices (CI). Briefly, combined dose-response curves were fitted to Chou-Talalay lines (21) , which are derived from the law of mass action and described by the equation: log(f a /f u ) ¼ m log(D) À m log(Dm), in which f a is the fraction affected, f u is the fraction unaffected, D is the dose, D m is the medianeffect dose, and m is the coefficient signifying the shape of the dose-response curve. The CI values were calculated using the equation:
, where Dx1 and Dx2 are the inhibitor and virus doses, respectively, that are required to achieve a particular f a , and D1 and D2 are the doses of the 2 agents (combined treatment) required for achieving the same f a . CI < 1, CI ¼ 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively.
Immunoblots
Cells were treated with virus at MOI of 1.5, collected at indicated times after infection, and cell pellets lysed in RIPA (radioimmunoprecipitation assay) buffer (Boston Bioproducts) with a cocktail of protease and phosphatase inhibitors (Roche). A total of 12.5 mg of protein was separated by 10% SDS-PAGE and transferred to PVDF (polyvinylidene difluoride) membranes by electroblotting. After blocking with 5% nonfat dry milk in TBS-Tween 20, membranes were incubated at 4 C overnight with the following antibodies (1:1,000): Akt, phosphorylated Akt (p-Akt; Ser473), phosphorylated Akt (Thr308), cleaved PARP (all from Cell Signaling Technology), ICP4 (USBiological), or actin (Sigma), followed by incubation with appropriate HRP (horseradish peroxidase)-conjugated goat anti-rabbit or anti-mouse secondary antibodies (1:5,000; Promega) for 1 hour at room temperature. Protein-antibody complexes were visualized using ECL (Amersham Bioscience).
Assay of caspase activity
Cells seeded into 96-well plates (5,000 cells/well) in triplicate were infected, LY294002 (20 mmol/L) or vehicle alone added 10 hours later, and caspase-3/7 activity evaluated 16 hours after infection using the Caspase-Glo 3/7 Assay Kit (Promega) according to the manufacturer's instruction.
Animal experiments
All in vivo procedures were approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital. For safety evaluation, female A/J mice, 6 weeks of age (NCI, Frederick, MD), were stereotactically inoculated (right striatum, 2.5-mm lateral from Bregma and 2.5-mm deep) with virus in 3 mL of virus buffer (150 mmol/L NaCl, 20 mmol/L Tris, pH 7.5) and euthanized when moribund. For efficacy studies, female athymic mice, 6 to 8 weeks of age (NCI) were stereotactically implanted (right striatum, 2.5-mm lateral from Bregma and 2.5-mm deep) with dissociated BT74 cells (1 Â 10 5 in 3 mL). On day 8, randomly grouped mice were treated by intratumoral injection of MG18L or virus buffer in 3 mL, followed 12 hours later with intraperitoneal injection of LY294002 or solvent daily for 5 days. For mice surviving 100 days, the absence of tumor tissue was macroscopically confirmed. For histologic studies, mice (28 days after tumor implantation) were treated with mock, MG18L, and/or LY294002 (days 28 and 29). Upon sacrifice brains were removed, fixed in 4% paraformaldehyde, and frozen sections subjected to X-gal and hematoxylin staining or immunocytochemistry with antibodies against human specific nuclei (Millipore), cleaved caspase-3 (Cell Signaling Technology), nestin (Santa Cruz Biotech), or b-gal (mouse from Sigma or rabbit from Millipore), followed by incubation with appropriate FITC (fluorescein isothiocyanate)-and Cy3-conjugated secondary antibodies (Jackson ImmunoResearch) and DAPI (4 0 ,6-diamidino-2-phenylindole).
Statistics
Comparisons of data in viral replication and caspase-3/7 assays were carried out using a 2-tailed Student's t test (unpaired). Survival was analysed by Kaplan-Meier curves with comparisons by log-rank test. p values less than 0.05 were considered statistically significant.
Results
Central nervous system safety and selectivity of MG18L MG18L is a new oHSV generated for GBM therapy that contains a deletion of the U S 3 gene and a LacZ insertion inactivating ICP6 (U L 39; Fig. 1A ). As isogenic controls, we used FD6, containing only the same ICP6 insertion in strain F, and R7041 with only the U S 3 deletion. Similar to G207, replication of MG18L was highly compromised in human astrocytes compared with parental R7041 and FD6. In U87 human glioma cells, MG18L replicated to a greater extent than G207 and somewhat less than R7041 and FD6 (Fig. 1B) . For oHSV to be translatable to the clinic for delivery in the brain, it is critical that it is not neuropathogenic. To examine this, highly HSV-1 susceptible A/J mice were inoculated intracerebrally and evaluated for neurologic symptoms. All mice inoculated with as little as 4 Â 10 2 plaque-forming units (pfu) of wildtype HSV-1 (strain F) died, whereas all mice inoculated with 4 Â 10 6 pfu of MG18L (the highest dose obtainable in 3 mL) or FD6 survived. In contrast, this dose of R7041 killed 90% of mice (Table 1) . We further quantified neurologic deficits using a scoring scale for morbidity, with 4 of 6 mice inoculated with FD6 (4 Â 10 6 pfu) showing moderate symptoms, whereas 2 of 8 mice inoculated with MG18L at this dose exhibited only mild transient symptoms (Fig. 1C) . At a 10-fold lower dose, only 2 of 6 R7041-inoculated mice did not show deficits (Fig. 1C) . Thus, we conclude that MG18L is safe and selective for glioma cells.
Effects of MG18L against human GSCs in vitro
All GSCs tested were susceptible to MG18L replication, with virus yield being similar to R7041 in GBM8 and GBM13 and 4-to 5-fold less in GBM4 and BT74, whereas G207 does not replicate ( Fig. 2A) . One activity of U S 3 protein is to inhibit Akt phosphorylation at Ser473 induced by HSV infection (17, 18) . Phosphorylation of Akt is induced by FD6 and G207 in GBM4 and BT74, respectively, even though G207 does not replicate, as illustrated by shutoff of immediate early ICP4 expression (Fig. 2B) . In MG18L-infected GSCs, p-Akt (Ser473 but not Thr308) levels are further increased and remain stable or continue to increase with time (Fig. 2B) . The in vitro efficacy of MG18L was compared with FD6 and G47D in GSCs. FD6 was most effective at killing GSCs, whereas MG18L was similar to G47D, except in GBM8 (Fig. 3A) . The virus yields for G47D and FD6 were previously reported (15) . This was similar in glioma cell lines U87 and T98G ( Supplementary  Fig. S2B ).
Human GSCs exhibit variable sensitivities to PI3K/Akt pathway inhibitors in vitro
The PI3K/Akt signaling pathway, commonly activated in cancer, is one of the most active targets for drug development. As a prelude to examining the interaction between MG18L and PI3K/Akt pathway inhibitors, we determined the GSC sensitivity to inhibitors of PI3K (GDC-0941), Akt (triciribine), mTOR/PI3K (BEZ235), and nonspecific PI3K (LY294002; ref. 23 ). GBM13 was the least sensitive to all 4 inhibitors, followed by BT74, whereas GBM4 and GBM8 were quite sensitive (Fig. 3B) . Triciribine ($250 mmol/L) had no effect on GBM13 viability, so its ED 50 was not obtainable. Both U87 and T98G exhibited a similar range of inhibitor sensitivities as BT74 (Supplementary Table S1 ). 
MG18L synergizes with PI3K/Akt pathway inhibitors to inhibit human GSCs in vitro
One of the rationales for the construction of MG18L was its postulated ability to sensitize cancer cells to PI3K/Akt pathway inhibitors. MG18L and LY294002 synergized in killing 3 of the 4 GSCs, whereas the interaction in human astrocytes was antagonistic to additive (Fig. 3C-G) . Synergy was dependent on the U S 3 deletion, as the interactions of FD6 and G47D (U S 3 þ oHSV) with LY294002 were mostly additive or antagonistic (Fig. 3C-F) . Similarly, the interactions in glioma cell lines (U87, T98G) were synergistic only for U S 3 À R7041 and MG18L ( Supplementary Fig. S3A ).
Synergy in U87 cells was not affected by the order of addition ( Supplementary Fig. S3A ). As LY294004 has a broad inhibitor profile across many PI3Ks and protein kinases (24), we examined the interactions of MG18L with selective PI3K/Akt pathway inhibitors that have been in clinical trial. Both triciribine and GDC-0941 synergized with MG18L to kill GBM4 and BT74 ( Fig. 3H and I) , whereas the dual PI3K/mTOR inhibitor BEZ235 only synergized in GBM13 (Fig. 3J) . Because GBM13 was resistant to triciribine (Fig. 3B ), we were unable to carry out a synergy analysis; however, a nontoxic dose of triciribine (30 mmol/L) enhanced killing by MG18L (data not shown). The interactions were similar in the glioma cells lines, with BEZ235 only strongly synergistic in T98G ( Supplementary  Fig. S3B-D) .
The combination of MG18L and LY294002 activate apoptotic pathways in glioma cells in vitro Treatment of BT74 or U87 cells with LY294002 did not increase MG18L replication and virus yield (Supplementary Fig. S4 ), indicating that this is not the mechanism underlying synergy. Because U S 3 blocks apoptosis in HSV-infected cells (16, 25) , we hypothesized that the combination of MG18L and PI3K/Akt pathway inhibitors enhanced apoptosis in glioma cells, contributing to the observed synergy. Caspase-3 and -7 are common effector caspases of both the intrinsic and extrinsic apoptotic pathways. GSCs and U87 infected with FD6 or MG18L showed increased levels of caspase-3/7 activity, with MG18L being significantly more effective than FD6
( Fig. 4A-D and Supplementary Fig. S5B ). Treatment of all GSCs and U87 cells, except GBM8 where synergistic killing was not observed, with MG18L and LY294002 showed significantly higher activities of caspase-3/7, compared with treatment with either alone (Fig. 4A-D and Supplementary Fig. S5B ). The combination of FD6 and LY294002 did not produce an increase in caspase activity ( Figure 3F .
showing the involvement of the lack of U S 3. As an additional readout for apoptosis, we examined cleaved PARP. Consistent with the results from the caspase-3/7 activity assay, an increased level of cleaved PARP was observed with the combination, except for GBM8 (Fig. 4E-H and Supplementary Fig. S5A ). In all cells, including GBM8, LY294002 treatment inhibited Akt activation (Fig. 4E-H and Supplementary Fig. S5A ). These results support the view that synergy is because of increased apoptosis. Blocking caspase activation with a pan-caspase inhibitor, Z-VAD-FMK, before treatment with MG18L and LY294002, impaired synergy in BT74, GBM4, and U87 cells (Fig. 4I and Supplementary Fig. S5C and D).
MG18L treatment of human GSC-derived intracerebral tumors
To evaluate the in vivo efficacy of MG18L, we used BT74-derived intracerebral tumors. Histopathologically, this GSC forms aggressive tumors with high levels of vascularity and intratumoral hemorrhage ( Fig. 5A, top; ref. 15 ), a hallmark of GBM in humans. MG18L efficiently infected and spread within the tumor, as illustrated by the extensive X-gal staining at 36 hours postinfection, which was more extensive than at 12 hours (Fig. 5A, bottom) . Sections were doubly immunostained with antibodies against human nuclear antigen (identifies BT74 cells) and b-galactosidase (identifies MG18L-infected cells), confirming MG18L spread within the tumor tissue (Fig. 5B) . Most of the cells in the tumors stained positive for nestin and these were susceptible to MG18L infection ( Supplementary Fig. S6 ). Treatment of mice bearing established BT74 tumors with a single injection of MG18L significantly extended their survival (Fig. 5C ). Median survival increased from 32.5 days for mock to 41 days with MG18L, with 1 animal surviving 100 days.
LY294002 enhances the therapeutic efficacy of MG18L in vivo
LY294002 treatment alone of BT74 tumor-bearing mice was only modestly effective, with a prolongation of median survival by 5.5 days (Fig. 5C ). Combination with MG18L was much more efficacious than either treatment alone, with 50% of mice surviving long term (Fig. 5C ). At 100 days, when all surviving mice were sacrificed, we did not detect tumor macroscopically. Similar results were obtained in a U87 intracerebral tumor model (Supplementary Fig. S7 ). Because combination treatment increased apoptosis in vitro (Fig. 4) , we examined BT74 tumor sections from mice for the presence of apoptotic cells (cleaved caspase-3 immunocytochemistry). Mock treatment did not induce detectable cleaved caspase-3 within the tumor, whereas LY294002 induced scattered positive cells ( Fig. 5D and E) . In contrast, MG18L infection induced a significant number of cleaved caspase-3-positive cells, which was further increased in combination with LY294002 ( Fig. 5D and E) , further supporting the hypothesis that apoptosis is a key mediator of improved efficacy.
Discussion
We have constructed a new oHSV vector, MG18L, containing a U S 3 deletion and ICP6 mutation that is both "safe" after intracerebral inoculation in HSV-susceptible mice and efficacious against GSCs, warranting clinical translation for GBM and possibly other tumors. The nonessential HSV U S 3 gene is a serine-threonine kinase with multiple biological functions, including blocking virus and exogenously induced apoptosis (16, 26) , so that its loss should engender tumor selectivity, although this still remains to be shown. In fact, U S 3 mutants in both HSV-1 and HSV-2 have been shown to have oncolytic activity (18, 27) . Other U S 3 activities that may be pertinent include phosphorylation of histone deacetylase (HDAC) 1 and HDAC2 blocking activity (28) , phosphorylation of IFN-g receptor a blocking downstream signaling (29) , and inhibiting virus-induced Akt activation (17, 18) . While R7041, with a single U S 3 mutation, was found to be very attenuated for pathogenicity in the periphery (18, 30, 31) , it was not after intracerebral inoculation (32, 33) . We found that R7041 had an LD 50 (lethal dose) of about 4 Â 10 5 pfu in A/J mice, whereas others reported LD 50 values of 1.8 Â 10 6 and 1 Â 10 5 pfu (32, 34) . Therefore, to improve safety, we combined the U S 3 deletion with an ICP6 mutation that further attenuates neurovirulence (Fig. 1C) and increases sensitivity to antivirals yet does not greatly reduce virus replication in GSCs (15, 35) . After intracerebral inoculation, MG18L exhibited a favorable safety profile that was comparable to g34.5 deletion mutants such as G207 and G47D, which have been safely administered to GBM patients (12, 14, 36) .
MG18L replicates well in GSCs and glioma cell lines, but not human astrocytes, and was very cytotoxic to GSCs in vitro, similar to G47D but less than FD6. While the addition of the ICP6 mutation to U S 3-deleted oHSV reduces replication in some GSCs, this is offset by decreased replication in astrocytes and improved safety. The mechanism underlying MG18L selectivity for GSCs, as well as apoptotic pathway function, remains to be determined. As expected, GSC infection with MG18L induced higher levels of p-Akt than FD6 infection. There are at least 10 inhibitors targeting the PI3K/Akt pathway in clinical trial including for glioma (7, 23) . MG18L synergized with PI3K/Akt inhibitors (LY294002, triciribine, and GDC-0941) in killing GSCs, except for GBM8, but not human astrocytes. Recently, it was reported that increased p-Akt, in response to DNAdamaging agent doxorubicin, correlated with PI3K inhibitor synergy (37) , possibly through a similar mechanism as with oHSV. Synergy was dependent on the U S 3 deletion, as other oHSVs expressing U S 3 (G47D and FD6) did not synergize (Fig. 3) . In contrast, synergy did not seem to correlate with how susceptible cells were to the PI3K/Akt inhibitors or MG18L alone, as the ED50 values varied more than 10-fold, and GBM8 had very similar sensitivities as GBM4 (Fig. 3) . Interestingly, the dual PI3K/mTOR inhibitor, BEZ235, was found to only synergize with MG18L in GBM13 and was mostly antagonistic in GBM4 and BT74.
GBM13 was much less sensitive to the PI3K/Akt pathway inhibitors than the other GSCs and astrocytes, although synergy was also observed in T98G cells, which was quite sensitive to the inhibitors alone. GBM13 is the only GSC tested that did not express PTEN (data not shown), and T98G has a PTEN mutation (38) . We tried to examine synergy with the mTOR inhibitor rapamycin but could not obtain reliable dose-response curves for analysis of synergy. However, when a single dose of rapamycin was combined with serial dilutions of MG18L in GBM4 or BT74, the reduction in cell viability was much less than additive, which may have contributed to the antagonistic interaction with BEZ235.
PI3K inhibition with LY294002 did not affect MG18L replication, which could have been one mechanism for synergy. Instead, the mechanism seems to be due to were sacrificed on day 30. Shown is a representative section of the brain with untreated BT74 tumor (hematoxylin and eosin staining) illustrating intratumoral hemorrhage (arrow). Bottom, mice treated with MG18L (2 Â 10 6 pfu) on day 28 were sacrificed 12 hours (left) and 36 hours (right) later. Sections were stained with X-gal (blue) to indicate MG18L infected cells. B, a region at the edge of the tumor from a 36 hour pi brain after immunostaining with antibodies against b-gal (green; MG18L infected cells) and human nucleus (red; BT74 cells), followed by DAPI (total nuclei; scale bar ¼ 100 mm). Virus was injected to the right of the displayed field. C, Kaplan-Meier survival curves of mice bearing BT74 tumors after treatment with intratumoral MG18L (2 Â 10 6 pfu) or mock, and intraperitoneal LY294002 (LY; 25 mg/kg/d) or vehicle (mock, n ¼ 10; MG18L, n ¼ 10; LY294002, n ¼ 6; combination, n ¼ 6). P < 0.05 (mock vs. LY294002 and LY294002 vs. MG18L þ LY294002), P < 0.0005 (mock vs. MG18L; log-rank test). D, mice with BT74 tumors treated with mock, MG18L, LY294002, or the combination were sacrificed 36 hours after MG18L injection. Brains were sectioned and tumors immunostained with antibodies to b-gal (green; MG18L) and cleaved caspase-3 (red; apoptosis) followed by DAPI (scale bars ¼ 100 mm). E, the ratio of cleaved caspase-3-positive cells/total was determined in 3 randomly selected fields. *, P < 0.05; **, P < 0.01. enhanced apoptosis in combination-treated cells. Interestingly, only in MG18L-infected GBM8 cells, apoptosis was not increased by LY294002. Thus, synergy with LY294002 could be impaired or abrogated in the presence of the pancaspase inhibitor Z-VAD-FMK in BT74, GBM4, and U87 cells ( Supplementary Figs. S4 and 5) . This supports the view that apoptosis induced by HSV infection that is not blocked by U S 3 is suppressed by activated Akt, balancing competing U S 3 altered pathways and making the cells very sensitive to inhibition of Akt signaling. Inhibition of the PI3K/Akt pathway in glioma has been reported to either induce apoptosis or autophagy (39) (40) (41) (42) , and sensitize cells to chemotherapy-induced apoptosis (43) . LY294002 treatment of GSCs significantly induced apoptosis in GBM4 and GBM8 but not GBM13 or BT74. The range of interactions observed in the different GSCs illustrates the complexity of the PI3K/Akt pathway in GBM, with its multiple feedback loops overlaid with genetic alterations at different nodes in the pathway, as well as potential interactions with the MEK (MAP/ERK kinase) pathway (44) . Further genetic analysis of the GSCs may identify alterations underlying sensitivity to inhibitors at different steps in the PI3K/Akt pathway and provide insights for future stratification of patients in any clinical trials with inhibitors in this pathway.
As a proof-of-concept study, we examined the combination of LY294002 with MG18L for in vivo therapy in mice bearing BT74 tumors. Combination treatment significantly prolonged the survival of mice, with 50% long-term survivors, compared with either agent alone. Synergy in vitro resulted in a 6.5-fold reduction in LY294002 dose at the ED 50 , to a more obtainable dose in vivo. While synergy in vitro was not affected by the temporal order of addition, for this in vivo experiment we administered MG18L prior to LY294002 to allow for induction of Akt activation by MG18L infection, followed by Akt inhibition by molecular targeting drugs. It will be important for clinical translation to further characterize the effect of administration schedule on efficacy with clinically relevant inhibitors. Although, we found that the combination treatment increased apoptosis both in vitro (Fig. 4 ) and in vivo ( Fig. 5D and E) , there may be additional factors contributing to the enhanced efficacy of the combination in vivo. For example, the antiangiogenic properties of PI3K/Akt/mTOR inhibitors (45, 46) and disruption of tumor interstitial space produced by enhanced apoptosis may have helped the spread of MG18L in the tumor tissue (47) . In summary, MG18L is effective in killing human glioma cells including GSCs, and the therapeutic efficacy can be enhanced by combination with PI3K/Akt pathway inhibitors. This strategy of using an oncolytic virus to alter a cancer pathway so that it sensitizes cancer cells to small molecule inhibitors that molecularly target these pathways is a novel one that should be applicable to other oHSV mutants, signaling pathways, and cancers.
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